A Phase 3 interventional study of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine and Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Meningitis, Meningococcal Meningitis and Meningococcal Infections, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 30 sites in 2 countries. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-05.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Meningitis, Meningococcal by Sanofi — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Sanofi.
Among the 24 studies in Meningitis, Meningococcal by Sanofi, this one is the 14th largest by enrollment of the 23 interventional ones that give a count, is one of 7 that started in 2016, is one of 13 in phase 3, and was the 14th registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →None of the 24 studies in Meningitis, Meningococcal by Sanofi is open now. The open studies under Meningitis, Meningococcal, anywhere →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 15 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 13 · Phase 4 3
First in 2006; this study’s year is marked. 7 started in 2016.
This study's enrollment of 810 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 907 across the 23 interventional studies, 100 across the 1 observational. Of the 24 that completed or were terminated, 22 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Meningitis, Meningococcal by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the study was to describe the safety and antibody response to booster administration with Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine in participants who received their first quadrivalent meningococcal Conjugate vaccine dose in the past 4-10 years.
Primary Objective:
Secondary Objectives:
Observational Objectives:
Healthy adolescents and adults who had received 1 dose of a quadrivalent meningococcal Conjugate vaccine 4 to 10 years previously were randomized to receive either 1 dose of MenACYW Conjugate vaccine or licensed Menactra®. All participants underwent immunogenicity assessment at baseline (pre-vaccination) and post-vaccination and were also evaluated for safety up to Day 180 post-vaccination. In addition, a subset had an additional blood sample collected at 6 days post-vaccination for immunogenicity assessment.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
This study's enrollment of 810 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Browse Meningitis, Meningococcal studies →Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
First submitted after Sanofi Pasteur became part of Sanofi.
Compared within Meningitis, Meningococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Meningitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy, meningococcal vaccine-primed adolescents (greater than or equal to \[\>=\] 15 to less than \[\< \]18 years) or adults (\>= 18 years) received a single dose of a MenACYW Conjugate vaccine on Day 0.
Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Healthy, meningococcal- vaccine-primed adolescents (\>= 15 to \< 18 years) or adults (\>= 18 years) received a single dose of Menactra ® vaccine on Day 0.
Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
0.5 milliliter (mL), Intramuscular
Also known as: MenACYW Conjugate vaccine
0.5 mL, Intramuscular
Also known as: Menactra®
Percentage of Participants With Seroresponse to Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine
The serum bactericidal assay using human complement (hSBA) vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8.
Time frame: Day 30 (post-vaccination)
Percentage of Participants With Seroresponse to Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine at Day 6 After Vaccination
The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8.
Time frame: Day 6 (post-vaccination)
Geometric Mean Titers Against Meningococcal Serogroups A, C, Y, and W Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine
Meningococcal antibody responses against Serogroups A, C, Y, and W were measured by hSBA.
Time frame: Day 30 (post-vaccination)
Number of Participants With Solicited Injection Site Reactions or Systemic Reactions Following Vaccination With Either MenACYW Conjugate Vaccine or Menactra® Vaccine
A Solicited Reaction (SR) was an Adverse Event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: Pain (Grade 1: no interference with activity, Grade 2: some interference with activity, Grade 3: significantly prevent daily activity), erythema and swelling (Grade 1: \>=25 millimeter \[mm\] to \<= 50 mm, Grade 2: \>=51 to \<=100 mm, Grade 3: \> 100 mm). Solicited systemic reactions: Fever (Grade 1: \>=38.0 degree Celsius (°C) to \<=38.4°C, Grade 2: \>=38.5°C to \<=38.9 °C, Grade 3: \>= 39°C), headache, malaise, and myalgia (Grade 1: no interference with activity, Grade 2: some interference with activity, Grade 3: significant; prevents daily activity. Number of participants with any of the Grade (1, 2 or 3) and with each Grade (1, 2 and 3) solicited injection-site and systemic reactions were reported.
Time frame: Within 7 days post-vaccination
Study participants were enrolled in 30 centers from 15 April 2016 to 02 August 2016.
| Milestone | MenACYW Conjugate Vaccine | Menactra ® |
|---|---|---|
| Started | 403 | 407 |
| Vaccinated | 402 | 407 |
| Completed | 396 | 402 |
| Not completed | 7 | 5 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Lost to follow-up | 3 | 2 |
The serum bactericidal assay using human complement (hSBA) vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8.
| percentage of participants | MenACYW Conjugate Vaccine | Menactra ® |
|---|---|---|
| Serogroup A | 92.2 (89.0 to 94.7) | 87.1 (83.4 to 90.3) |
| Serogroup C | 97.1 (94.9 to 98.6) | 91.8 (88.6 to 94.3) |
| Serogroup Y | 97.4 (95.3 to 98.7) | 95.6 (93.1 to 97.4) |
| Serogroup W | 98.2 (96.3 to 99.3) | 90.7 (87.4 to 93.4) |
The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:16 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post-vaccination for participants with pre-vaccination hSBA titers \>= 1:8.
| percentage of participants | MenACYW Conjugate Vaccine | Menactra ® |
|---|---|---|
| Serogroup A | 72.7 (59.0 to 83.9) | 66.1 (53.0 to 77.7) |
| Serogroup C | 83.6 (71.2 to 92.2) | 87.1 (76.1 to 94.3) |
| Serogroup Y | 90.9 (80.0 to 97.0) | 83.9 (72.3 to 92.0) |
| Serogroup W | 94.5 (84.9 to 98.9) | 83.9 (72.3 to 92.0) |
Meningococcal antibody responses against Serogroups A, C, Y, and W were measured by hSBA.
| titers (1/dilution) | MenACYW Conjugate Vaccine | Menactra ® |
|---|---|---|
| Serogroup A | 497 (436 to 568) | 296 (256 to 343) |
| Serogroup C | 2618 (2227 to 3078) | 599 (504 to 711) |
| Serogroup Y | 2070 (1807 to 2371) | 811 (699 to 941) |
| Serogroup W | 1747 (1508 to 2025) | 723 (614 to 853) |
A Solicited Reaction (SR) was an Adverse Event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: Pain (Grade 1: no interference with activity, Grade 2: some interference with activity, Grade 3: significantly prevent daily activity), erythema and swelling (Grade 1: \>=25 millimeter \[mm\] to \<= 50 mm, Grade 2: \>=51 to \<=100 mm, Grade 3: \> 100 mm). Solicited systemic reactions: Fever (Grade 1: \>=38.0 degree Celsius (°C) to \<=38.4°C, Grade 2: \>=38.5°C to \<=38.9 °C, Grade 3: \>= 39°C), headache, malaise, and myalgia (Grade 1: no interference with activity, Grade 2: some interference with activity, Grade 3: significant; prevents daily activity. Number of participants with any of the Grade (1, 2 or 3) and with each Grade (1, 2 and 3) solicited injection-site and systemic reactions were reported.
| Participants | MenACYW Conjugate Vaccine | Menactra ® |
|---|---|---|
| Pain-Any Grade | 178 | 196 |
| Pain-Grade 1 | 141 | 154 |
| Pain-Grade 2 | 33 | 34 |
| Pain-Grade 3 | 4 | 8 |
| Erythema-Any Grade | 20 | 6 |
| Erythema-Grade 1 | 18 | 5 |
| Erythema-Grade 2 | 2 | 1 |
| Erythema-Grade 3 | 0 | 0 |
| Swelling-Any Grade | 16 | 3 |
| Swelling-Grade 1 | 13 | 1 |
| Swelling-Grade 2 | 3 | 2 |
| Swelling-Grade 3 | 0 | 0 |
| Fever-Any Grade | 0 | 2 |
| Fever-Grade 1 | 0 | 0 |
| Fever-Grade 2 | 0 | 1 |
| Fever-Grade 3 | 0 | 1 |
| Headache-Any Grade | 151 | 134 |
| Headache-Grade 1 | 90 | 73 |
| Headache-Grade 2 | 52 | 47 |
| Headache-Grade 3 | 9 | 14 |
| Malaise-Any Grade | 110 | 108 |
| Malaise-Grade 1 | 62 | 64 |
| Malaise-Grade 2 | 37 | 30 |
| Malaise-Grade 3 | 11 | 14 |
| Myalgia-Any Grade | 146 | 156 |
| Myalgia-Grade 1 | 98 | 120 |
| Myalgia-Grade 2 | 40 | 27 |
| Myalgia-Grade 3 | 8 | 9 |
Collected over Adverse event (AE) data were collected from Day 0 up to Day 30 post-vaccination. Solicited Reaction (SR) were collected from Day 0 up to Day 7 post-vaccination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: MenACYW Conjugate Vaccine | 0/402 (0%) | 5/402 (1.2%) | 255/402 (63.4%) |
| Group 2: Menactra ® | 0/407 (0%) | 4/407 (1%) | 263/407 (64.6%) |
| Event | Group 1: MenACYW Conjugate Vaccine | Group 2: Menactra ® |
|---|---|---|
| CholelithiasisHepatobiliary disorders | 1/402 | 0/407 |
| Allergy To Arthropod StingImmune system disorders | 1/402 | 0/407 |
| AppendicitisInfections and infestations | 1/402 | 0/407 |
| Clavicle FractureInjury, poisoning and procedural complications | 1/402 | 0/407 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 1/402 | 0/407 |
| Intestinal PerforationGastrointestinal disorders | 0/402 | 1/407 |
| Chest PainGeneral disorders | 0/402 | 1/407 |
| Major DepressionPsychiatric disorders | 0/402 | 1/407 |
| Suicidal IdeationPsychiatric disorders | 0/402 | 1/407 |
| Event | Group 1: MenACYW Conjugate Vaccine | Group 2: Menactra ® |
|---|---|---|
| Injection Site PainGeneral disorders | 178/402 | 196/407 |
| MyalgiaMusculoskeletal and connective tissue disorders | 147/402 | 158/407 |
| HeadacheNervous system disorders | 155/402 | 137/407 |
| MalaiseGeneral disorders | 110/402 | 108/407 |
Analysis was performed on all randomized participants.
| Age, Continuous(Years) | MenACYW Conjugate Vaccine | Menactra ® | Total |
|---|---|---|---|
| Mean | 20.0 ± 5.96 | 19.9 ± 5.59 | 20.0 ± 5.77 |
| Sex: Female, Male(Participants) | MenACYW Conjugate Vaccine | Menactra ® | Total |
|---|---|---|---|
| Female | 207 | 200 | 407 |
| Male | 196 | 207 | 403 |
| Race (NIH/OMB)(Participants) | MenACYW Conjugate Vaccine | Menactra ® | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 11 | 3 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 40 | 46 | 86 |
| White | 342 | 340 | 682 |
| More than one race | 8 | 17 | 25 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(Participants) | MenACYW Conjugate Vaccine | Menactra ® | Total |
|---|---|---|---|
| United States | 403 | 407 | 810 |
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Apr 2016 to primary completion in Dec 2016, 8 months.
Results were first posted in Jun 2020, 3 years 5 months after primary completion. A results delay was requested in Jan 2018.
Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 20. This study's 8 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi Pasteur, a Sanofi Company →